FDA Investigating Hypocalcemia Risk In Patients Using Prolia Osteoporosis Drug
SILVER SPRING, Md. — The Food and Drug Administration announced Nov. 22 that it is investigating risk of severe hypocalcemia in certain patients getting injections of Prolia brand denosumab, an osteoporosis...To view the full article, register now.
Already a subscriber? Click here to view full article